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changes in triglycerides in olanzapine-treated women 
(n = 32) versus ziprasidone-treated women (n = 44) trend-
ing toward signiﬁcance (p = 0.09). CONCLUSIONS: In
a six-week trial, men treated with olanzapine experienced
an increase in CHD risk that was signiﬁcant versus a
decrease in men treated with ziprasidone, while changes
in risk did not differ signiﬁcantly between olanzapine-
and ziprasidone-treated women. These results paralleled
changes in lipid proﬁle. Investigation is warranted into
effects of long-term treatment with atypical antipsy-
chotics on risk of CHD.
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CLIENT AND STAFF INVOLVEMENT IN FORMAT
DESIGN OF A HEALTH-RELATED QUALITY OF
LIFE SURVEY FOR INDIVIDUALS WITH
SCHIZOPHRENIA,THE SCHIZOPHRENIA
OUTCOMES ASSESSMENT PROJECT (SOAP)
SURVEY
Barr JT, Schumacher GE, Ohman SM, Quimby CM
Northeastern University, Boston, MA, USA
OBJECTIVES: Since end-users of survey may have design
format preferences that are undetected by survey devel-
oper/administrators, we elicited client and staff input and
preferences for three survey formats of a 51-item health-
related quality of life survey for community-residing indi-
viduals with schizophrenia. METHODS: Using cognitive
interviews and visual analogue preference ratings (0–100
scale), we sought qualitative and quantitative input from
29 community-residing clients with schizophrenia and 33
staff members at four sites concerning their preferences
for three formats of the 51-item Schizophrenia Outcomes
Assessment Project (SOAP-51) Survey: a 6-page booklet
with responses horizontally listed below each item, a 
4-page version with responses to the right of each item,
and a compressed 2-page version of the former. Survey
formats were presented in randomized order. Staff was
also asked their preference for four versus ﬁve-response
format. Clients were individually interviewed in 15–20
minutes sessions; staff had individual (20–30 minutes) or
group (45–60 minute) sessions. RESULTS: Clients pre-
ferred the booklet and 4-page format over the 2-page
version; respective VAS values of 70.1, 68.9, and 47.0 
(p = 0.012). Qualitatively, clients indicated that the 2-
page was too compressed and that the 4-page format
made it easier to link the response to the question. Staff
preferred 4 responses to 5 (84.0 versus 46.1, p < 0.0001)
because they perceived little distinction between two of
the ﬁve response levels. Staff had a preference trend
toward the 4-page format over the booklet or 2-page
(68.6, 58.6, and 58.9 respectively, p = 0.22). When asked
their ﬁrst choice, 47% of staff indicated 4-page; 34%, 2-
page; and 19%, booklet. CONCLUSIONS: Clients pre-
ferred booklet and 4-page formats; staff preferred 4-page
and 2-page formats. Based on this input, we have selected
the 4-page format, the common preference of both
groups. Survey developers should incorporate end-users
to provide insight into format preferences and cognitive
processing.
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TREATMENT WITH PSYCHOSTIMULANTS IS
ASSOCIATED WITH DECREASED RATES OF
SUBSTANCE ABUSE AND IMPROVED SCHOOL
OUTCOMES AMONG CHILDREN WITH AD/HD
Katusic SK, Barbaresi WJ, Colligan RC,Weaver AL,
Mrazek DA, Jacobsen SJ
Mayo Clinic, Rochester, MN, USA
OBJECTIVES: To study the long-term impact of psy-
chostimulant treatment on substance abuse and school
outcomes in a population-based cohort of AD/HD cases.
METHODS: Subjects included 282 AD/HD research
identiﬁed cases treated with psychostimulant medication
and 81 AD/HD cases that were never treated with 
psychostimulants. These subjects are subsets of the 363
research identiﬁed cases from a population-based birth
cohort, born in Rochester, MN 1976–1992 who
remained in Rochester after age 5 (N = 5,718). All 363
cases were followed from age 5 until emigration, death,
school graduation, drop out. Among 282 treated with
stimulants, 85% (N = 239) of cases were treated with
methylphenidate. Data on type of psychostimulant,
dosage prescribed (Methylphenidate Equivalent Units),
start/stop dates were collected from medical and school
records. The same resources were retrospectively and lon-
gitudinally examined for the documentation of substance
abuse and school outcomes. Associations between 
psychostimulant treatment and outcomes were evaluated
using general linear and logistic regression models.
RESULTS: Of the AD/HD cases treated with stimulants,
16.3% had documented substance abuse compared to
23.5% cases not treated (OR = 0.6; 95% CI = 0.3–1.2;
p = 0.14). Cases treated at an earlier age were less likely
to have documented substance abuse (p = 0.025) as well
as those treated for a longer duration (p = 0.17). Cases
with higher average daily psychostimulant dosage had
higher reading scores (r = 0.14, p = 0.025). Cases treated
with psychostimulants were absent signiﬁcantly less than
those who were not treated (p = 0.024). Furthermore,
cases treated longer were absent less (r = -0.18, p =
0.003). CONCLUSIONS: Our large, longitudinal, popu-
lation-based, study demonstrates that psychostimulant
treatment is associated with decreased substance abuse
and improved school outcomes among AD/HD cases.
Our study conﬁrms the positive impact and importance
of long-term treatment with psychostimulants and reﬂects
an improvement in the lives of children with AD/HD.
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PSORIASIS AND DEPRESSIVE
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Taïeb C1, Garrido JA2, Myon E1
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OBJECTIVE: Chronic skin diseases have a heavy impact
on the physical and mental well-being of the patient. 
This is conﬁrmed by the large number of quality of life
studies that exist. Paradoxically, no study has evaluated
depressive symptomatology in Spanish patients with 
dermatosis. This was why it was decided to carry out, in
association with Accion Psoriasis (a Spanish Patient
Support Group), an evaluation of the depressive symp-
tomatology of patients suffering from psoriasis.
METHODS: The CES-D scale (Center for Epidemiologic
Studies—Depression scale) was developed in the USA at
the National Institute of Mental Health to perform epi-
demiological studies of depressive symptomatology in the
general population. The CES-D scale was sent to 1300
patients with psoriasis, members or supporters of Accion
Psoriasis. The completed questionnaires were returned in
prepaid envelopes. RESULTS: Out of the 1300 question-
naires sent out in March 2003. At mid-March 2003, 300
questionnaires were returned: response rate 23%. The
presented results concerned the 106 ﬁrst questionnaires
analysed. The male/female gender ratio was as follows
54/46. Depressive symptomatology was observed in 
44% of men (average score 17.8) and 55% of women
(average score 21). This difference between men and
women was not statistically signiﬁcant. An evaluation
according to the age at diagnosis was also carried out: 2
groups were identiﬁed: diagnosis at 16 years of age or
younger versus a group diagnosed after the age of 16.
Depressive symptomatology was observed in 54% of
patients in the ﬁrst group versus 46% of patients in the
second group. CONCLUSION: These preliminary results
show the importance of the psychological impact of 
dermatosis, especially psoriasis. Global management of
patients seems essential for patients suffering from
chronic dermatosis.
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PSORIASIS AND DEPRESSIVE
SYMPTOMATOLOGY: ITALIAN RESULTS
Taïeb C1, Prioglio P2, Myon E1
1Pharmaco Economics & Quality of Life Department,
Boulogne Billancourt, France; 2Pierre Fabre Italie, Boulogne
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OBJECTIVE: Chronic skin diseases have a heavy impact
on the physical and mental well-being of the patient. This
is conﬁrmed by the large number of quality of life studies
that exist. Paradoxically, no study has evaluated depres-
sive symptomatology in Italian patients with dermatosis.
This was why it was decided to carry out, in association
with ADIPSO (an Italian Patient Support Group), an eval-
uation of the depressive symptomatology of patients suf-
fering from psoriasis. Tools: the CES-D scale (Center for
Epidemiologic Studies—Depression scale) was developed
in the USA at the National Institute Of Mental Health to
perform epidemiological studies of depressive symptoma-
tology in the general population. METHOD: The CES-D
scale was remitted by Italian Dermatologists to the ﬁrst
5000 patients with psoriasis coming to their ofﬁce. The
completed questionnaires were returned in prepaid
envelopes. RESULTS: Out of the 5000 questionnaires
remitted in February and March 2003. At mid-March
2003, 3000 questionnaires were returned: response rate
60%. The presented results concerned the 100 ﬁrst ques-
tionnaires analysed. The male/female gender ratio was as
follows 61/39. Depressive symptomatology was observed
in 34% of men (average score 17.2) and 62% of women
(average score 21). This difference between men and
women was statistically signiﬁcant (p = 0.007). An eval-
uation according to the education level was also carried
out: Two groups were identiﬁed: patients having a
primary/secondary education level (n = 69) versus pa-
tients having a higher education level (n = 31). Depres-
sive symptomatology was observed in 51% of patients in
the ﬁrst group versus 32% of patients in the second
group. This difference according to the education level
was statistically signiﬁcant (p < 0.02). CONCLUSION:
These preliminary results show the importance of the 
psychological impact of dermatosis, especially psoriasis.
Global management of patients seems essential for
patients suffering from chronic dermatosis.
PMH23
DEVELOPMENT AND ASSESSMENT OF 
HEALTH STATE UTILITIES FOR ATTENTION
DEFICIT/HYPERACTIVITY DISORDER IN
CHILDREN USING PARENT PROXY REPORT
Matza LS1, Secnik K2, Rentz AM3, Mannix S1, Revicki DA1,
Sallee FR4
1MEDTAP International, Inc, Bethesda, MD, USA; 2Eli Lilly and
Company, Indianapolis, IN, USA; 3MEDTAP International, Inc,
Sindelﬁngen, Germany; 4University of Cincinnati, Cincinnati,
OH, USA
OBJECTIVES: Attention deﬁcit/hyperactivity disorder
(ADHD) is a behavioral disorder, originating in child-
hood, with broad impairment in academic performance,
social functioning, and quality of life. ADHD health state
utilities have not previously been assessed using parent
ratings. Health state utilities are needed to calculate
quality-adjusted life years (QALYs), a critical measure of
outcomes in cost-effectiveness studies. The purpose of this
study was to use standard gamble (SG) utility methodol-
ogy to assess parent preferences for ADHD health states.
METHODS: Parents of children diagnosed with ADHD
completed SG utility interviews, in which they rated their
child’s current health and 11 hypothetical health states
(e.g., untreated ADHD; stimulant treatment; atomoxetine
treatment, a new non-stimulant). The hypothetical health
states were developed based on physician interviews, pub-
lished literature, and unpublished clinical trial data.
Parents reported children’s symptoms using the 18-item
ADHD-RS. Construct validity and health state differences
were examined with correlations, t-tests, and ANOVAs.
RESULTS: Participants were 43 parents of children with
ADHD. The mean parent SG rating of their child’s
